This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ICF International (ICFI) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICF (ICFI) delivered earnings and revenue surprises of 11.81% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Maximus (MMS) Stock Now
by Zacks Equity Research
Solid track record of dividend payments boosts Maximus (MMS).
Maximus (MMS) Down 5.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Maximus (MMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MAXIMUS (MMS) Misses on Q3 Earnings, Trims '22 EPS View
by Zacks Equity Research
MAXIMUS's (MMS) third-quarter 2022 earnings and revenues decline year over year.
Maximus (MMS) Misses Q3 Earnings Estimates
by Zacks Equity Research
Maximus (MMS) delivered earnings and revenue surprises of -20.41% and 3.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Booz Allen Hamilton (BAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Booz Allen (BAH) delivered earnings and revenue surprises of 6.60% and 2.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Maximus (MMS) Stock in Your Portfolio For Now
by Zacks Equity Research
With more than 40 years of experience, Maximus (MMS) has grown to be a leading operator of government health and human services programs globally.
Maximus (MMS) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Maximus (MMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MAXIMUS (MMS) Q2 Earnings Top, Stock Down 8.8% on Tepid EPS View
by Zacks Equity Research
MAXIMUS (MMS) second-quarter fiscal 2022 earnings fall, while revenues rise year over year.
Maximus (MMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Maximus (MMS) delivered earnings and revenue surprises of 9.18% and 8.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Maximus (MMS) Stock to Your Portfolio Now
by Zacks Equity Research
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally.
Wall Street Analysts See a 31% Upside in Maximus (MMS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 31.3% upside potential for Maximus (MMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Maximus (MMS) Up on Strategic Acquisitions Amid High Debt
by Zacks Equity Research
Maximus' (MMS) expertise in business process management, and its ability to deliver cost-effective, efficient and high-scale solutions, position it as a lucrative partner to governments.
Wall Street Analysts See a 33% Upside in Maximus (MMS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 33.3% upside potential for Maximus (MMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MAXIMUS (MMS) Beats on Q1 Earnings, Raises '22 Revenue View
by Zacks Equity Research
MAXIMUS's (MMS) first-quarter 2022 earnings and revenues improve year over year.
Maximus (MMS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Maximus (MMS) delivered earnings and revenue surprises of 40% and 5%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Maximus (MMS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Maximus (MMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Maximus (MMS) Stock Now
by Zacks Equity Research
Strategic acquisitions and investor-friendly measures boost Maximus (MMS) stock. However, high debt is a headwind.
Investor-Friendly Steps Aid MAXIMUS (MMS), High Debt Ails
by Zacks Equity Research
MAXIMUS (MMS) rides on solid shareholder-friendly measures and strategic acquisitions. However, a high debt balance is a concern.
MAXIMUS (MMS) Q4 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
New COVID-19 response work drives MAXIMUS (MMS) Q4 fiscal 2021 performance.
Maximus (MMS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Maximus (MMS) delivered earnings and revenue surprises of 21.35% and 2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Maximus (MMS) a Suitable Stock for Value Investors Now?
by Vedika Agarwal
Let's see if Maximus (MMS) stock is a good choice for value-oriented investors right now from multiple angles.
Navient (NAVI) to Exit From Federal Student Loan Servicing
by Zacks Equity Research
Navient (NAVI) will transfer the accounts of nearly six million federal student loan borrowers to Maximus, thereby ceasing the loan payment collections on behalf of the U.S. Department of Education.
Here's Why You Should Retain MAXIMUS (MMS) Stock for Now
by Zacks Equity Research
Shareholder-friendly measures and strategic acquisitions drive MAXIMUS (MMS). However, high debt is a headwind.
Shareholder-Friendly Steps Aid MAXIMUS (MMS), High Debt Ails
by Zacks Equity Research
Solid track record of dividend payments is encouraging for MAXIMUS (MMS). However, debt-laden balance sheet is a concern.